Statutory Scheme News Today

The Association of the British Pharmaceutical Industry (ABPI) has published an executive summary [1] of its consultation response to the government's proposed changes to the Statutory Scheme for branded medicines [2].In its response, the ABPI acknowledged and broadly supported the government’s intention to bri...

On finding that failure on the part of assessee to comply with the pre-condition for obtaining the deduction cannot be condoned either by the statutory authorities or by the courts, the Bangalore ITAT...

On 20 November 2023, the UK Government and the Association of the British Pharmaceutical Industry (“ABPI”) ‒ the industry body representing the…

The Pharmaceutical Journal from the Royal Pharmaceutical Society

Life sciences leaders unite to condemn radical plans to rewrite medicines scheme

ABPI response to government Statutory Scheme riseThe government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject to the Statutory Scheme for branded medicines from 24.4% to 27.5% [1].In February, the Association of the British Pharmaceutical Industry warned that the propose...

The ABPI and Lilly have responded to the UK government’s confirmed plans to increase the payment percentage in the Statutory Scheme.

The Department of Health and ICAEW have reviewed the audit reports required under the scheme to ensure they continue to comply with International Standards on Auditing (UK).

The ABPI has urged immediate government action is needed against the planned UK statutory revenue clawback rate rise for branded medicines.

Major industry names depart leaving UK pricing deal in serious jeopardy - News - PharmaTimes